Ionis Pharmaceuticals Partners to Advance Antisense Oligonucleotide Medicines for Rare Genetic Diseases

Innovative Partnership Aims to Advance Antisense Oligonucleotide Medicines for Underserved Patients

In a significant advancement within the biotechnology sector, n-Lorem and GondolaBio announce a collaboration aimed at developing new antisense oligonucleotide (ASO) medicines for patients suffering from nano-rare genetic diseases. This partnership seeks to harness n-Lorem’s extensive ASO discovery platform and expertise to address the pressing unmet needs of a patient population often overlooked in drug development. By focusing on specific biological markers associated with these rare conditions, n-Lorem aims to identify promising ASO candidates, which GondolaBio will subsequently advance through clinical development.

The collaboration is pivotal not only for the scientific community but also for the patients desperately seeking effective treatments. n-Lorem, a nonprofit foundation, will receive upfront payments and research funding from GondolaBio, alongside potential milestone payments tied to the successful discovery and development of new ASO therapies. This financial support underscores the commitment from GondolaBio, which has garnered $300 million in funding from notable investors, including Patient Square Capital and Viking Global Investors. The infusion of capital enables GondolaBio to expand its reach and capabilities, building on its foundation as a clinical-stage biotechnology company formed from subsidiaries of BridgeBio Pharma.

Stanley Crooke, M.D., Ph.D., Chairman and CEO of n-Lorem, emphasizes the organization's capacity to scale its operations while ensuring high-quality outcomes in response to the increasing demand for innovative treatments. The partnership with GondolaBio represents a strategic alignment that not only enhances the research and development landscape but also highlights the urgent need to innovate in genetic disease therapeutics. By combining n-Lorem’s expertise in ASO technology with GondolaBio’s robust clinical development framework, the collaboration sets a new standard for addressing the complexities of treating patients with genetic diseases.

In addition to the collaboration, the expanding role of GondolaBio, which has grown to encompass eight subsidiaries each focused on unique drug development programs, illustrates the dynamic nature of the biotechnology industry. This growth reflects a broader trend towards innovative solutions in healthcare, particularly in areas that have historically lacked sufficient therapeutic options.

The partnership between n-Lorem and GondolaBio not only stands to transform the treatment landscape for nano-rare genetic diseases but also signifies a hopeful leap forward for patients who have long awaited effective therapies. By fostering collaboration between nonprofit and clinical-stage entities, the biotechnology sector continues to evolve, promising a brighter future for underserved patient populations.